A Phase 3 Trial of Brepocitinib in Dermatomyositis
New England Journal of Medicine · 14.05.2026 · 394 (19) · 1883-1893
DOI: 10.1056/nejmoa2503531 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 14.05.2026. Verfasst von Ruth Ann Vleugels und 41 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Brigham Department of Dermatology, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Dermatomyositis, Janus Kinase 1, Janus Kinase Inhibitors, TYK2 Kinase. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Priovant Therapeutics.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mass General Brigham Department of Dermatology, Harvard Medical School, Boston.
- Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.
- Division of Rheumatology, Department of Medicine, University of Chicago, Chicago.
- Department of Dermatology, Mayo Clinic, Scottsdale, AZ.
- Division of Rheumatology, Department of Medicine, Emory University, Atlanta.
- Department of Dermatology, University of California, San Francisco, San Francisco.
ORCID-Profile: Julie J Paik
Förderung
- Priovant Therapeutics
Zitieren
APA
Vleugels, R. A., Paik, J. J., Bauer Ventura, I., Mangold, A. R., Gandiga, P. C., Haemel, A., Chinoy, H., Hussain, Y. M., Sivakumar, K., Griger, Z., Lee, E. B., Bozan, F., Hsu, C. Y., Femia, A., Dimachkie, M. M., Min, M. S., Mozaffar, T., Charles-Schoeman, C., Fernandez, D. R., …, & VALOR Investigators (2026). A Phase 3 Trial of Brepocitinib in Dermatomyositis. New England Journal of Medicine, 394(19), 1883-1893. https://doi.org/10.1056/nejmoa2503531
Vancouver
Vleugels RA, Paik JJ, Bauer Ventura I, Mangold AR, Gandiga PC, Haemel A, et al. A Phase 3 Trial of Brepocitinib in Dermatomyositis. New England Journal of Medicine. 2026;394(19):1883-1893. doi:10.1056/nejmoa2503531
BibTeX
@article{Vleugels2026,
author = {Vleugels, Ruth Ann and Paik, Julie J and Bauer Ventura, Iazsmin and Mangold, Aaron R and Gandiga, Prateek C and Haemel, Anna and Chinoy, Hector and Hussain, Yessar M and Sivakumar, Kumaraswamy and Griger, Zoltan and Lee, Eun Bong and Bozan, Francisca and Hsu, Chung-Yuan and Femia, Alisa and Dimachkie, Mazen M and Min, Michelle S and Mozaffar, Tahseen and Charles-Schoeman, Christina and Fernandez, David R and Onajin, Oluwakemi and Campanilho-Marques, Raquel and Marder, Galina and Ernste, Floranne and Schiopu, Elena and Sluzevich, Jason and Pearson, David and Lindsey, Stephen and Luggen, Michael and Bubb, Michael R and Boh, Erin and Maganti, Rashmi and Heinlen, Latisha and Shaw, Katharina S and Cascino, Matthew D and Mudd, Paul N and Vencovsky, Jiri and Fernandez, Anthony P and Fiorentino, David and Christopher-Stine, Lisa and Werth, Victoria P and Aggarwal, Rohit and VALOR Investigators, VALOR Investigators},
title = {A Phase 3 Trial of Brepocitinib in Dermatomyositis},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {19},
pages = {1883--1893},
doi = {10.1056/nejmoa2503531}
}
EUVIMED